This decision paves the way for broader applications of this therapeutic strategy in BRAF-mutant thyroid cancers beyond ATC, including papillary and poorly differentiated thyroid carcinomas, which collectively account for a large proportion of BRAF-driven thyroid tumors. This evidence concerns the gene BRAF and thyroid gland carcinoma.